Starling Oncology Warrant
STLNW
11 hedge funds and large institutions have $94.9K invested in Starling Oncology Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
399% more capital invested
Capital invested by funds: $19K → $94.9K (+$75.8K)
0.1% less ownership
Funds ownership: 4.74% → 4.65% (-0.1%)
21% less funds holding
Funds holding: 14 → 11 (-3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$130 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$280 |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$87 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$62 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
STLNW Hedge Fund Activity: Q1 2025 in Review
11 of the 7,476 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q1 2025, worth a combined $94.9K — up 399% from $19K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of STLNW and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Clear Street, adding an estimated $130. The largest seller was Walleye Capital, exiting entirely with an estimated $280 sold.
- 11 institutional investors held Starling Oncology Warrant (STLNW) as of Q1 2025, down from 14 in Q4 2024.
- Funds reported $94.9K of Starling Oncology Warrant stock for Q1 2025, up 399% quarter-over-quarter.
- 0 funds opened new Starling Oncology Warrant positions in Q1 2025 and 3 closed out, a net change of -3 holders.
- The largest Starling Oncology Warrant buyer in Q1 2025 was Clear Street, an estimated $130 added.
- The largest Starling Oncology Warrant seller in Q1 2025 was Walleye Capital, an estimated $280 sold.
Based on aggregated 13F filings for Q1 2025.